Jason Butler
Stock Analyst at Citizens
(4.67)
# 186
Out of 5,150 analysts
141
Total ratings
51.37%
Success rate
46.91%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Market Outperform | $88 → $96 | $62.27 | +54.17% | 18 | Feb 25, 2026 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Market Outperform | $8 | $3.74 | +113.90% | 2 | Jan 5, 2026 | |
| NSRX Nasus Pharma | Initiates: Market Outperform | $19 | $5.00 | +280.00% | 1 | Dec 18, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $114 → $131 | $116.77 | +12.19% | 5 | Dec 16, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $9.86 | +92.70% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $70.02 | +31.39% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $4.37 | +174.60% | 8 | Oct 9, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $29.34 | -4.57% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $23.39 | +58.19% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $15.99 | +143.90% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.55 | +69.01% | 11 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $115 → $100 | $25.17 | +297.30% | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $30.39 | +25.04% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $8.93 | +101.57% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.91 | +37.46% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $749.56 | -6.48% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $3.28 | +174.39% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $7.12 | +166.85% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.83 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $8.50 | +494,017.65% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $15.41 | +652.76% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.75 | +89.47% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.68 | - | 1 | Dec 2, 2020 |
Cytokinetics
Feb 25, 2026
Maintains: Market Outperform
Price Target: $88 → $96
Current: $62.27
Upside: +54.17%
Ironwood Pharmaceuticals
Jan 5, 2026
Upgrades: Market Outperform
Price Target: $8
Current: $3.74
Upside: +113.90%
Nasus Pharma
Dec 18, 2025
Initiates: Market Outperform
Price Target: $19
Current: $5.00
Upside: +280.00%
ABIVAX Société Anonyme
Dec 16, 2025
Maintains: Market Outperform
Price Target: $114 → $131
Current: $116.77
Upside: +12.19%
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $9.86
Upside: +92.70%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $70.02
Upside: +31.39%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $4.37
Upside: +174.60%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $29.34
Upside: -4.57%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $23.39
Upside: +58.19%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $15.99
Upside: +143.90%
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.55
Upside: +69.01%
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $25.17
Upside: +297.30%
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $30.39
Upside: +25.04%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $8.93
Upside: +101.57%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.91
Upside: +37.46%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $749.56
Upside: -6.48%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $3.28
Upside: +174.39%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $7.12
Upside: +166.85%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $6.83
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $8.50
Upside: +494,017.65%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $15.41
Upside: +652.76%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.75
Upside: +89.47%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.68
Upside: -